At SYG BIOTECH, we're pioneering the future of biotechnological solutions with a relentless commitment to enhancing health outcomes globally. Our latest innovation, a cutting-edge in vitro platform, is set to transform the landscape of therapeutic protein selection.
Our state-of-the-art platform accelerates the discovery and development of new therapeutic proteins, including VHHs, DARPINs, and other peptides. These proteins are engineered to precisely target immune checkpoints such as PD-1/PD-L1, pivotal in treating various diseases, especially in oncology by inhibiting these checkpoints. Our products can play a crucial role in cancer therapies, potentially turning the tide against this global challenge.
Alongside our therapeutic protein selection platform, we have developed an innovative rapid detection kit for PD-1 and PD-L1, as well as their inhibitors. This user-friendly kit enables researchers to detect and analyze these biomarkers with unprecedented speed and accuracy. Our technology not only facilitates the rapid development of personalized and effective therapies but also empowers the scientific community to push forward the boundaries of what's possible in medical science.